HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma

HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma

Abstract Background Immunotherapy (IO) plus tyrosine kinase inhibitor (TKI) emerged as standard first‐line therapy for advanced renal cell carcinoma (RCC). The heme Oxygenase 1 (HMOX1) pathway is involved in tumor development and treatment resistance, which may affect the efficacy of TKI + IO. Metho...

Full description

Bibliographic Details
Main Authors: Xianglai Xu, Sihong Zhang, Ying Wang, Yanjun Zhu, Jiajun Wang, Jianming Guo
Format: Article
Language:English
Published: Wiley 2023-05-01
Series:Cancer Medicine
Subjects:
heme oxygenase 1
immune checkpoint inhibitor
renal cell carcinoma
T‐cell dysfunction
tyrosine kinase inhibitor
Online Access:https://doi.org/10.1002/cam4.5787

Internet

https://doi.org/10.1002/cam4.5787

Similar Items